Industry
Biotechnology
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Loading...
Open
5.81
Mkt cap
20M
Volume
22K
High
5.96
P/E Ratio
-0.45
52-wk high
27.36
Low
5.76
Div yield
N/A
52-wk low
2.77
Portfolio Pulse from
November 15, 2024 | 5:00 pm
Portfolio Pulse from
November 13, 2024 | 12:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 7:50 pm
Portfolio Pulse from Avi Kapoor
October 24, 2024 | 11:40 am
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 11:20 am
Portfolio Pulse from Benzinga Newsdesk
October 14, 2024 | 4:28 pm
Portfolio Pulse from Benzinga Newsdesk
October 14, 2024 | 11:17 am
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 2:12 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 8:13 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 12:35 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.